ArticleThe Lancet. Oncology2022

HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study.

Vivek Naranbhai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.